Quick Answer
Harmony Biosciences Holdings, Inc. reported Cash and Equivalents of $752.50 million for fiscal year 2025.
Harmony Biosciences Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $752.50M | +66.1% |
| 2024 | $453.00M | +45.4% |
| 2023 | $311.66M | +27.8% |
| 2022 | $243.78M | +4.0% |
| 2021 | $234.31M | +2.5% |
| 2020 | $228.63M | +834.8% |
| 2019 | $24.46M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $647.00M | +67.0% | +18.5% |
| June 30, 2025 | $546.05M | +72.1% | +11.7% |
| March 31, 2025 | $489.00M | +46.9% | +7.9% |
| December 31, 2024 | $453.00M | +45.4% | +16.9% |
| September 30, 2024 | $387.37M | +19.3% | +22.1% |
| June 30, 2024 | $317.30M | -0.0% | -4.7% |
| March 31, 2024 | $332.98M | +15.6% | +6.8% |
| December 31, 2023 | $311.66M | +27.8% | -4.0% |
- Harmony Biosciences Holdings, Inc. showed an increase of +66.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Harmony Biosciences Holdings, Inc.’s cash and equivalents has grown by 2976.8% (from $24.46 million to $752.50 million).
- The most recent figure is from Harmony Biosciences Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: